---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-107314"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:21:08.906453+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioMarin discontinues VOXZOGO trials in Turner, SHOX, ACAN after SCFE safety events

## Summary
- Discontinued dosing and enrollment in Phase 2 CANOPY trials for Turner syndrome, SHOX-deficiency, and ACAN-deficiency.
- Decision follows slipped capital femoral epiphysis (SCFE) events in two investigator-sponsored trials; SCFE not seen in BioMarin's own trials or in >5,000 achondroplasia patients.
- Phase 2 CANOPY trials for Noonan syndrome and idiopathic short stature (ISS) without ACAN-deficiency will continue as planned.
- Over 10,000 patient-years of safety data in achondroplasia shows no SCFE cases; VOXZOGO remains approved for achondroplasia.

## SEC filing metadata
- accession: 0001193125-26-107314
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/0001193125-26-107314-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526107314/d114815d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-107314
- JSON: https://secwatch.observer/filing/0001193125-26-107314.json
- Plain text: https://secwatch.observer/filing/0001193125-26-107314.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.